MPNs

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, provided an update on developments, unmet needs, and future directions for the treatment of patients with myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed the importance of overall survival data in JAK inhibitor trials and how to transition between agents. This is the second of 2 articles based on this event.

Raajit K. Rampal, MD, PhD, discusses the MANIFEST-2 trial, a phase 3 study comparing ruxolitinib vs pelabresib and ruxolitinib combined with placebo for the treatment of myelofibrosis.

Ropeginterferon alfa is now a recommended first-line treatment for patients with polycythemia vera, according to the National Comprehensive Cancer Network’s updated guidelines.

During a Targeted Oncology™ Case-Based Roundtable™ event, Andrew Kuykendall, MD, reviewed adverse events and dosing issues related to the 4 approved JAK inhibitors in patients with myelofibrosis.

In an interview with Targeted Oncology, Douglas Tremblay, MD, discussed the significance of cytoreductive therapy in mitigating thrombotic risk in myeloproliferative neoplasms.

During a Targeted Oncology™ Case-Based Roundtable™ event, Raajit K. Rampal, MD, gave an overview of the classification, risk assessment, and current therapy options for patients with myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bart Scott, MD, discussed JAK inhibitor options and the data from the PERSIST-2 trial of pacritinib. This is the first of 2 articles based on this event.

Magrolimab will no longer be in development as a treatment option for patients with hematologic malignancies.

Douglas Tremblay, MD, discusses the factors which influence the decision to recommend cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Tamoxifen, a selective estrogen receptor modulator, shows potential as a line of treatment in some patients with myeloproliferative neoplasms.

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.

Douglas Tremblay, MD, discusses the use and potential benefits and risks of cytoreduction for patients with essential thrombocytopenia and polycythemia vera.

Haifa Kathrin Al-Ali, MD, discussed findings from the phase 1/2 CA011-023 study of BMS-986158 combined with ruxolitinib or fedratinib in myelofibrosis.

Findings from the MOMENTUM study evaluating momelotinib demonstrated symptom, spleen, and anemia benefits in myelofibrosis compared with danazol in previously treated patients with anemia and intermediate- or high-risk myelofibrosis.

Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.

In the second article of a 2-part series, Pankit Vachhani, MD, highlights the impact ruxolitinib has had, and continues, to have in treatment for patients with myelofibrosis and how physicians should manage this treatment for their patients.

During a Targeted Oncology™ Case-Based Roundtable™ event, Rami Komrokji, MD, discussed issues related to dosing and management of patients receiving ruxolitinib for myelofibrosis.

During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.

Pelabresib plus ruxolitinib demonstrated a 35% or greater reduction in spleen volume and trended toward reducing mean absolute total symptom score (TSS) as well as improving TSS reduction by 50% at 24 weeks in patients with JAK inhibitor-naive myelofibrosis.

Andrew Srisuwananukorn, MD, discusses the main findings from research of an artificial intelligence-powered machine learning algorithm which evaluated digital whole-slide images of diagnostic bone marrow biopsies and accurately differentiated prefibrotic primary myelofibrosis from essential thrombocythemia.

The use of the experimental navitoclax in combination with ruxolitinib produced impactful results for patients with myelofibrosis.

Anthony Hunter, MD, discusses JAK inhibitor resistance and optimal strategies for treatment of patients with myelofibrosis.

In the first article of a 2-part series, Pankit Vachhani, MD, discusses what makes classical cases of myeloproliferative neoplasms unique and how ruxolitinib impacts their reduction of spleen volume.

Based on in vitro data, pacritinib led to a 4-fold higher potency for inhibition of the hepcidin regulator ACVR1 vs momelotinib among patients with cytopenic myelofibrosis and led to an increase in red blood cell transfusion independence.